article thumbnail

STAT+: Oregon suspends a portion of its drug transparency law found to be unconstitutional

STAT

In a victory for the pharmaceutical industry, Oregon officials have suspended a portion of a contentious state law designed to bring more transparency to prescription drug pricing. At the time, such laws were pursued by several states as a way to force the pharmaceutical industry to justify price hikes that were straining budgets.

article thumbnail

STAT+: The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat

STAT

Then, in 2018, she finally found a drug that kept her ADHD in check.  STAT is co-publishing this article by Tradeoffs. Lisa Ann Trainor struggled to stay on top of schoolwork, hold a job or even perform basic tasks like laundry for six exhausting years.   Continue to STAT+ to read the full story…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Making Medicines Affordable: The Role of Generics

Drug Patent Watch

The FDA has also demonstrated that greater competition among generic drug makers can lead to lower generic drug prices. Studies have shown that the market entry of just a few generic competitors can yield generic prices below the brand price, and that generic drug prices decline with additional competition.

article thumbnail

The XBI biotech index hit its lowest point since 2018. No one knows what comes next.

STAT

Want to stay on top of the science and politics driving biotech today?    Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a look at biotech’s latest nadir, the virtues of Neanderthal DNA, and the sudden success of a decades-old idea in oncology. Read the rest…

article thumbnail

Opinion: Cutting-edge insulin is good. But it’s the ‘trailing edge’ of older versions that can keep it affordable

STAT

According to Yale researchers, 14% Americans who need insulin to control their diabetes spend more than 40% of their post-subsistence income (what is available after paying for food and housing) on the drug. Each new generation of insulin products has been marked by an increase in price.

Diabetes 289
article thumbnail

STAT+: Civica Rx considers moving into chemo drugs as shortages worsen

STAT

Frustrated by drug shortages and the price spikes that typically ensue, executives from large hospital systems launched the nonprofit Civica Rx to deal with the problem in September 2018. Although shortages are not new, the number of drugs in short supply has grown steadily for about two years.

Hospitals 289
article thumbnail

340B program reaches $100 billion in sales, while patients are left behind

PhRMA

The 340B Drug Pricing Program has grown yet again , exceeding $100 billion in sales in 2022 when 340B-priced medicines are measured at wholesale acquisition cost. year-over-year in 2022, continuing a trend in which 340B sales have almost doubled since 2018, outpacing growth of the total U.S. drug market.